This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Analysts' Actions: BBBY DAN JCI KORS X

Xylem was upgraded at DA Davidson to neutral from underperform. $34 price target. Company boosted its guidance and announced surprise growth, DA Davidson said.

Stock Comments/EPS Changes

Acadia Healthcare (ACHC) numbers, price target were raised at Jefferies. Shares are now seen reaching $47. Strong top-line growth and upside in margin expansion, Jefferies said. Estimates lifted into next year. Buy rating.

Actavis (ACT) estimates, price target were increased at Jefferies. Company expects double-digit organic growth after in-line third-quarter results. $168 price target and hold rating.

Archer-Daniels-Midland (ADM) numbers were increased at BMO Capital. Estimates were boosted through 2014. Company is seeing higher divisional profits and a higher LIFO benefit, BMO Capital said. Market perform rating and new $42 price target.

Aetna (AET) estimates, price target were lowered at BMO Capital. Estimates were cut through 2014. Company reduced its guidance, BMO Capital said. Outperform rating and new $70 price target.

Ameriprise (AMP) estimates, price target were boosted at Credit Suisse. Shares are now seen reaching $100. Estimates were also increased, given better asset management growth, Credit Suisse said. Neutral rating.

Cummins (CMI) estimates, price target were reduced at BMO Capital. Shares are now seen reaching $144. Estimates were also cut, given the company's new guidance, BMO Capital said. Outperform rating.

Dana estimates, price target are lowered at Jefferies. Weakness in commercial vehicles, Jefferies said. $23 price target and buy rating.

Gilead (GILD) estimates, price target were increased at Credit Suisse. Estimates were raised through 2015. Company is seeing higher sales and keeping a tight lid on costs, Credit Suisse said. Outperform rating and new $80 price target.

Gilead Sciences (GILD) price target was raised at J.P. Morgan to $85. Strong third-quarter with upside in HIV-related sales, J.P. Morgan said. Overweight rating.

L-3 Communications (LLL) estimates, price target were raised at Credit Suisse. Price target was increased to $97. Estimates were also increased, as the company is realizing higher margins.

LinkedIn (LNKD) estimates, price target were boosted at Credit Suisse. Shares are now seen reaching $288. Estimates were also increased, given the company's new guidance. Outperform rating.

Questcor Pharmaceuticals (QCOR) estimates, price target were increased at Jefferies. QCOR raised its numbers, said Jefferies. Very robust Acthar growth in rheumatology, Jefferies also said. $76 price target and buy rating.

Titan International (TWI) estimates, price target were lowered at Jefferies. TWI decreased its numbers into next year. Uncertainty reflecting commodity end markets and company execution, Jefferies said. $16 price target and Hold rating.

Valero (VLO) estimates, price target were raised at Credit Suisse. Shares are now seen reaching $40. Crude spreads have widened, Credit Suisse said. Neutral rating.

Vertex (VRTX) estimates, price target were cut at Credit Suisse. Shares are now seen reaching $78. Estimates were also reduced, given lower Incivek sales, Credit Suisse said. Neutral rating.

Western Union (WU) numbers were cut at Sterne Agee. Shares are now seen reaching $20. Estimates were also reduced, given the company's new guidance, Sterne Agee said. Buy rating.

>To submit a news tip, email: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
BBBY $71.41 0.00%
DAN $21.47 0.00%
JCI $51.10 0.00%
KORS $62.55 0.00%
X $23.26 0.00%

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs